Moderna, Inc. (NASDAQ: MRNA) has secured a supply contract for up to 160 million doses of COVID-19 vaccine candidates from the European Union. Moderna Inc. has earlier disclosed that its experimental COVID-19 vaccine has shown 94.5% effectiveness in limiting this novel disease. EU
